David Ferrick, PhD
David Ferrick, PhD, senior director of the Cell Analysis Division at Agilent Technologies

Immunotherapy is changing the landscape of cancer treatment, but most of the available tools are adapted and not purpose-built for this cell-centric workflow. A safe, potent, and persistent immune cell product depends on developers mustering the full repertoire of immune cell function; activation, proliferation, cell fate, cytotoxic killing, immunomodulation, and memory. All of which must be accomplished in the ever-changing, suppressive, and toxic tumor microenvironment.

Agilent is dedicated to supporting these next-generation cell therapies, providing key technologies to enable high-efficiency gene editing and assessment of real-time cell function, phenotype, fitness and fate. Used together, this tool bench provides the capability to measure and control immune cell function, thus enabling translational researchers and developers to achieve the necessary level of therapeutic potency and safety.

This eBook provides the latest recommendations from various leaders in immunotherapy research and their insights into exciting new developments. Their inspiration has guided and helped us compile these articles that showcase new analysis tools for scientists developing innovative cell-based solutions.


View eBook

  Sponsored by:
Agilent logo

Previous articleAtomwise, Hansoh Pharma Enter Into Up-to-$1.5B AI-Based Drug Discovery Partnership
Next article10x Genomics IPO Starts Out Strong, as Bio-Rad Files Third Patent Lawsuit